Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 383 - 424
Published: Nov. 8, 2024
Language: Английский
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Nov. 27, 2023
Abstract Immunotherapies have revolutionized the treatment paradigms of various types cancers. However, most these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory bispecific T cell engager and chimeric antigen receptor (CAR)-T cell. Although agents already achieved great success, only a tiny percentage patients could benefit from immunotherapies. Actually, immunotherapy efficacy is determined multiple components in tumor microenvironment beyond immunity. Cells innate arm system, such as macrophages, dendritic cells, myeloid-derived suppressor neutrophils, natural killer unconventional also participate cancer evasion surveillance. Considering that cornerstone antitumor response, utilizing immunity provides potential therapeutic options for control. Up to now, exploiting agonists stimulator interferon genes, CAR-macrophage -natural therapies, metabolic regulators, novel exhibited potent activities preclinical clinical studies. Here, we summarize latest insights into roles cells discuss advances arm-targeted strategies.
Language: Английский
Citations
84
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: July 22, 2024
Abstract Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles both normal physiology the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, growth factors like TGF-β, VEGF, EGF, can promote or inhibit growth, influence microenvironment, impact efficacy cancer treatments. Recent advances targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate system, progression, overcome resistance conventional therapies. In this review, we summarized current understanding implications cytokine chemokine signaling By exploring molecules biology response, highlighted development novel agents aimed at modulating combat The review elaborated on nature cytokines promoters suppressors tumorigenesis, depending context, discussed challenges opportunities presents for intervention. We also examined latest advancements targeted therapies, monoclonal antibodies, bispecific receptor inhibitors, fusion proteins, engineered variants, their metastasis, microenvironment. Additionally, evaluated potential combining therapies with other treatment modalities improve patient outcomes. Besides, focused ongoing research clinical trials that pivotal advancing our application cytokine- chemokine-targeted patients.
Language: Английский
Citations
60
Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)
Published: March 12, 2024
Abstract The programmed cell death 1 (PD-1) signaling pathway, a key player in immune checkpoint regulation, has become focal point cancer immunotherapy. In the context of cancer, upregulated PD-L1 on tumor cells can result T exhaustion and evasion, fostering progression. advent PD-1/PD-L1 inhibitor demonstrated clinical success by unleashing from exhaustion. Nevertheless, challenges such as resistance adverse effects have spurred exploration innovative strategies, with bispecific antibodies (BsAbs) emerging promising frontier. BsAbs offer multifaceted approach to immunotherapy simultaneously targeting other regulatory molecules. We focus recent advancements therapy particular emphasis development potential BsAbs, especially solid tumors. Various BsAb products PD-1 are discussed, highlighting their unique mechanisms action therapeutic potential. Noteworthy examples include anti-TGFβ × PD-L1, anti-CD47 anti-VEGF anti-4-1BB anti-LAG-3 anti-PD-1 CTLA-4 BsAbs. Besides, we summarize ongoing studies evaluating efficacy safety these agents. By unraveling intricacies microenvironment harnessing synergistic anti-PD-1/PD-L1 there exists elevate precision immunotherapy, ultimately enabling personalized treatment strategies tailored individual patient profiles.
Language: Английский
Citations
14
International Immunopharmacology, Journal Year: 2023, Volume and Issue: 126, P. 111186 - 111186
Published: Nov. 17, 2023
Language: Английский
Citations
22
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 23, 2024
Malignant cells are known to evade immune surveillance by engaging checkpoints which negative regulators of the system. By restoring T-lymphocyte mediated anti-tumor effect, checkpoint inhibitors (ICI) have revolutionized treatment solid tumors but met rather modest success in hematological malignancies. Currently, only FDA approved indications for ICI therapy classic hodgkin lymphoma and primary mediastinal B cell lymphoma. Multiple clinical trials assessed alone combination with standard care treatments other lymphomas, plasma neoplasms myeloid were noted limited efficacy. These mostly focused on PD-1/PDL-1 CTLA-4 inhibitors. Recently, there has been an effort target like LAG-3, TIM-3, TIGIT along improving strategies inhibition. Drugs targeting macrophage checkpoint, CD47, also being tested. Long term safety efficacy data from these ongoing studies eagerly awaited. In this comprehensive review, we discuss mechanism inhibitors, key takeaways reported results completed therapies context
Language: Английский
Citations
7
Trends in cancer, Journal Year: 2024, Volume and Issue: 10(5), P. 444 - 456
Published: Feb. 14, 2024
Language: Английский
Citations
6
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117298 - 117298
Published: Aug. 15, 2024
Immune checkpoint blocking (ICB), a tumor treatment based on the mechanism of T-cell activation, has shown high efficacy in clinical trials, but not all patients benefit from it. inhibitors (ICIs) do respond to cold tumors that lack effective infiltration well hot with sufficient infiltration. How convert an unresponsive into responsive is important topic cancer immunotherapy. Ferroptosis, newly discovered immunogenic cell death (ICD) form, great potential therapy. In process deeply understanding formation, it was found ferroptosis showed powerful immune-activating effect by improving infiltration, and combination ICB therapy significantly enhanced anti-tumor efficacy. This paper reviews complex relationship between T cells ferroptosis, as summarizes various mechanisms which enhances infiltration: reactivation reversal immunosuppressive microenvironment (TME), recent advances ICI targeted therapies, provides guidance for better tumors.
Language: Английский
Citations
5
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1440 - 1440
Published: Feb. 8, 2025
Antibody-based immune-stimulating drugs (ABIs) represent a transformative frontier in cancer immunotherapy, designed to reshape the tumor microenvironment and overcome immune suppression. This study highlighted recent advances ABIs, including antibody conjugates (ISACs), bispecific antibodies (BsAbs), checkpoint blockade enhancers, with focus on their mechanisms of action, clinical advancements, challenges. Preclinical findings revealed that ISACs effectively boost overall anti-cancer immunity by reprogramming tumor-associated macrophages, enhancing T cell activation, engaging other pathways. Similarly, BsAbs redirect cells tumors, achieving significant regression. Additionally, artificial intelligence (AI) is revolutionizing development ABIs optimizing drug design, identifying novel targets, accelerating preclinical validation, enabling personalized therapeutic strategies. Despite these challenges remain, resistance off-target effects. Future research should prioritize next-generation multifunctional antibodies, AI-driven innovations, combination therapies enhance efficacy expand applications. Connecting gaps could unlock full potential upgrading treatment improving outcomes for patients refractory or resistant tumors.
Language: Английский
Citations
0
BioDrugs, Journal Year: 2025, Volume and Issue: unknown
Published: March 19, 2025
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: April 25, 2025
Transforming growth factor-beta (TGF-β) has long been known to be associated with early embryonic development and organogenesis, immune supervision, tissue repair homeostasis in adults. TGF-β complex roles fibrosis cancer that may opposing at different stages of these diseases. Under pathological conditions, overexpression causes epithelial–mesenchymal transition, deposition extracellular matrix, formation cancer-associated fibroblasts, leading fibrotic disease or cancer. Fibroblasts, epithelial cells, cells are the most common targets TGF-β, while TGF-β-associated Given critical role its downstream molecules progression cancer, therapies targeting signaling appear a promising strategy. Preclinical clinical studies have investigated including antisense oligonucleotides, monoclonal antibodies, ligand traps. However, targeted therapy hindered by systemic cytotoxicity. This review discusses molecular mechanisms highlights for as therapeutic strategy related
Language: Английский
Citations
0